Reported Earnings • May 15
Full year 2026 earnings released: ₹2.38 loss per share (vs ₹4.86 loss in FY 2025) Full year 2026 results: ₹2.38 loss per share (improved from ₹4.86 loss in FY 2025). Revenue: ₹3.20b (down 4.4% from FY 2025). Net loss: ₹34.3m (loss narrowed 51% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 121 percentage points per year, which is a significant difference in performance. Reported Earnings • Jan 29
Third quarter 2026 earnings released: ₹3.09 loss per share (vs ₹1.32 profit in 3Q 2025) Third quarter 2026 results: ₹3.09 loss per share (down from ₹1.32 profit in 3Q 2025). Revenue: ₹709.1m (down 15% from 3Q 2025). Net loss: ₹44.5m (down 336% from profit in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 118 percentage points per year, which is a significant difference in performance. Anuncio • Jan 22
Chemfab Alkalis Limited to Report Q3, 2026 Results on Jan 28, 2026 Chemfab Alkalis Limited announced that they will report Q3, 2026 results on Jan 28, 2026 New Risk • Dec 24
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 1.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹6.32b market cap, or US$70.4m). New Risk • Nov 02
New major risk - Revenue and earnings growth Earnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹8.75b market cap, or US$98.6m). Reported Earnings • Nov 02
Second quarter 2026 earnings released: ₹1.40 loss per share (vs ₹0.37 loss in 2Q 2025) Second quarter 2026 results: ₹1.40 loss per share (further deteriorated from ₹0.37 loss in 2Q 2025). Revenue: ₹783.2m (down 4.4% from 2Q 2025). Net loss: ₹20.1m (loss widened 276% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. New Risk • Sep 25
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.69b (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Declared Dividend • Aug 22
Dividend of ₹1.25 announced Dividend of ₹1.25 is the same as last year. Ex-date: 4th September 2025 Payment date: 12th October 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (5% cash payout ratio). The dividend has remained flat since 7 years ago. However, payments have been volatile during that time. Reported Earnings • Aug 01
First quarter 2026 earnings released: EPS: ₹1.77 (vs ₹0.63 in 1Q 2025) First quarter 2026 results: EPS: ₹1.77 (up from ₹0.63 in 1Q 2025). Revenue: ₹929.0m (up 21% from 1Q 2025). Net income: ₹25.5m (up 184% from 1Q 2025). Profit margin: 2.7% (up from 1.2% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 118 percentage points per year, which is a significant difference in performance. Anuncio • Jul 31
Chemfab Alkalis Limited Approves Resignation C. S. Ramesh as Non- Executive and Non - Independent Director, Effective July 31, 2025 Chemfab Alkalis Limited at its board meeting held on 24 July, 2025, approved the resignation letter dated 31 July, 2025 submitted by Mr. C. S. Ramesh (Non- Executive and Non - Independent Director) of the Company was placed before the Board. The Board considered and approved the same. He will cease to hold office as Director of the Company with effect from the close of business hours on July 31, 2025. The company also inform that the Board of Directors considered and approved the reconstitution of the Audit Committee, Nomination and Remuneration Committee, CSR Committee, Stakeholders Relationship Committee of the Board: Consequent to resignation of Mr. C. S. Ramesh (Non- Executive and Non - Independent Director) effective 31 July, 2025. Anuncio • Jul 25
Chemfab Alkalis Limited to Report Q1, 2026 Results on Jul 31, 2025 Chemfab Alkalis Limited announced that they will report Q1, 2026 results on Jul 31, 2025 Reported Earnings • May 15
Full year 2025 earnings released: ₹4.86 loss per share (vs ₹18.53 profit in FY 2024) Full year 2025 results: ₹4.86 loss per share (down from ₹18.53 profit in FY 2024). Revenue: ₹3.41b (up 4.3% from FY 2024). Net loss: ₹69.4m (down 126% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 67% per year, which means it is well ahead of earnings. New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.4% net profit margin). Reported Earnings • Jan 31
Third quarter 2025 earnings released: EPS: ₹1.32 (vs ₹5.00 in 3Q 2024) Third quarter 2025 results: EPS: ₹1.32 (down from ₹5.00 in 3Q 2024). Revenue: ₹861.7m (flat on 3Q 2024). Net income: ₹18.8m (down 74% from 3Q 2024). Profit margin: 2.2% (down from 8.2% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 66% per year, which means it is well ahead of earnings. Anuncio • Jan 30
Chemfab Alkalis Limited Announces Resignation of B Vignesh Ram as Company Secretary and Compliance Officer Chemfab Alkalis Limited at the board of directors meeting held on January 30, 2025 announced that the resignation letter dated 23 January 2025 as submitted by Mr. B Vignesh Ram, Company Secretary & Compliance Officer of the Company was placed before the Board. Reason: To explore alternate career opportunities outside the organization. The Board considered and approved the same. The Board further authorized Mr. V M Srinivasan, Chief Executive Officer of the Company, to decide on the reliving date of Mr. B Vignesh Ram. New Risk • Jan 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (3.9% net profit margin). New Risk • Dec 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (3.9% net profit margin). Reported Earnings • Nov 05
Second quarter 2025 earnings released: ₹0.37 loss per share (vs ₹3.03 profit in 2Q 2024) Second quarter 2025 results: ₹0.37 loss per share (down from ₹3.03 profit in 2Q 2024). Revenue: ₹825.0m (up 3.7% from 2Q 2024). Net loss: ₹5.34m (down 112% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth. Anuncio • Sep 21
Chemfab Alkalis Limited Approves Dividend Chemfab Alkalis Limited at its AGM held on September 20, 2024 approved dividend of INR 1.25 per share. Upcoming Dividend • Sep 06
Upcoming dividend of ₹1.25 per share Eligible shareholders must have bought the stock before 13 September 2024. Payment date: 20 October 2024. Payout ratio is a comfortable 6.7% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). Anuncio • Aug 29
Chemfab Alkalis Limited, Annual General Meeting, Sep 20, 2024 Chemfab Alkalis Limited, Annual General Meeting, Sep 20, 2024, at 10:00 Indian Standard Time. Reported Earnings • Aug 09
First quarter 2025 earnings released: EPS: ₹0.63 (vs ₹6.70 in 1Q 2024) First quarter 2025 results: EPS: ₹0.63 (down from ₹6.70 in 1Q 2024). Revenue: ₹791.2m (flat on 1Q 2024). Net income: ₹8.96m (down 91% from 1Q 2024). Profit margin: 1.1% (down from 12% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Anuncio • Jul 26
Chemfab Alkalis Limited to Report Q1, 2025 Results on Aug 08, 2024 Chemfab Alkalis Limited announced that they will report Q1, 2025 results on Aug 08, 2024 Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹838, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 363% over the past three years. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹688, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 358% over the past three years. Valuation Update With 7 Day Price Move • May 29
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹523, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 263% over the past three years. Reported Earnings • May 23
Full year 2024 earnings released: EPS: ₹18.53 (vs ₹45.61 in FY 2023) Full year 2024 results: EPS: ₹18.53 (down from ₹45.61 in FY 2023). Revenue: ₹3.36b (up 1.4% from FY 2023). Net income: ₹263.2m (down 59% from FY 2023). Profit margin: 7.8% (down from 20% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to ₹695, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 451% over the past three years. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improves as stock rises 34% After last week's 34% share price gain to ₹586, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 360% over the past three years. Buy Or Sell Opportunity • Feb 23
Now 31% overvalued after recent price rise Over the last 90 days, the stock has risen 58% to ₹586. The fair value is estimated to be ₹448, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 70%. New Risk • Feb 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹7.20b market cap, or US$86.9m). Reported Earnings • Feb 09
Third quarter 2024 earnings released: EPS: ₹5.00 (vs ₹10.56 in 3Q 2023) Third quarter 2024 results: EPS: ₹5.00 (down from ₹10.56 in 3Q 2023). Revenue: ₹878.4m (up 4.6% from 3Q 2023). Net income: ₹71.0m (down 52% from 3Q 2023). Profit margin: 8.1% (down from 18% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 28
Second quarter 2024 earnings released: EPS: ₹3.03 (vs ₹9.22 in 2Q 2023) Second quarter 2024 results: EPS: ₹3.03 (down from ₹9.22 in 2Q 2023). Revenue: ₹810.4m (up 6.6% from 2Q 2023). Net income: ₹43.0m (down 67% from 2Q 2023). Profit margin: 5.3% (down from 17% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Aug 15
Upcoming dividend of ₹1.25 per share at 0.4% yield Eligible shareholders must have bought the stock before 22 August 2023. Payment date: 28 September 2023. Payout ratio is a comfortable 2.7% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%). Reported Earnings • Jul 28
First quarter 2024 earnings released: EPS: ₹6.70 (vs ₹15.10 in 1Q 2023) First quarter 2024 results: EPS: ₹6.70 (down from ₹15.10 in 1Q 2023). Revenue: ₹827.6m (down 16% from 1Q 2023). Net income: ₹95.1m (down 56% from 1Q 2023). Profit margin: 12% (down from 22% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Anuncio • Jul 18
Chemfab Alkalis Limited to Report Q1, 2024 Results on Jul 27, 2023 Chemfab Alkalis Limited announced that they will report Q1, 2024 results on Jul 27, 2023 Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹370, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 157% over the past three years. Reported Earnings • May 21
Full year 2023 earnings released: EPS: ₹45.61 (vs ₹20.36 in FY 2022) Full year 2023 results: EPS: ₹45.61 (up from ₹20.36 in FY 2022). Revenue: ₹3.37b (up 24% from FY 2022). Net income: ₹645.8m (up 125% from FY 2022). Profit margin: 19% (up from 11% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Anuncio • May 19
Chemfab Alkalis Limited Recommends Final Dividend Chemfab Alkalis Limited at its board meeting held on May 18, 2023, recommended to the shareholders for their approval in the upcoming annual general meeting a payment of INR 1.25 per share as final dividend. Buying Opportunity • May 11
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be ₹367, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 46%. Buying Opportunity • Apr 17
Now 21% undervalued Over the last 90 days, the stock is up 5.0%. The fair value is estimated to be ₹366, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 46%. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to ₹274, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 159% over the past three years. Recent Insider Transactions • Mar 27
Chief Executive Officer recently sold ₹5.8m worth of stock On the 23rd of March, Vaithamanithi Srinivasan sold around 25k shares on-market at roughly ₹232 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Vaithamanithi's only on-market trade for the last 12 months. Buying Opportunity • Feb 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 2.1%. The fair value is estimated to be ₹361, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 46%. Reported Earnings • Feb 08
Third quarter 2023 earnings released: EPS: ₹10.56 (vs ₹8.56 in 3Q 2022) Third quarter 2023 results: EPS: ₹10.56 (up from ₹8.56 in 3Q 2022). Revenue: ₹861.6m (up 11% from 3Q 2022). Net income: ₹149.4m (up 24% from 3Q 2022). Profit margin: 17% (up from 16% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Anuncio • Jan 16
Chemfab Alkalis Limited to Report Q3, 2023 Results on Feb 07, 2023 Chemfab Alkalis Limited announced that they will report Q3, 2023 results at 4:00 PM, Indian Standard Time on Feb 07, 2023 Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹258, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 54% over the past three years. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Non Executive Non Independent Director Nitin Cowlagi was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 05
Second quarter 2023 earnings released: EPS: ₹9.22 (vs ₹0.58 in 2Q 2022) Second quarter 2023 results: EPS: ₹9.22 (up from ₹0.58 in 2Q 2022). Revenue: ₹771.7m (up 31% from 2Q 2022). Net income: ₹130.4m (up ₹122.1m from 2Q 2022). Profit margin: 17% (up from 1.4% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹350, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 98% over the past three years. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 15% share price gain to ₹356, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 114% over the past three years. Upcoming Dividend • Aug 31
Upcoming dividend of ₹1.25 per share Eligible shareholders must have bought the stock before 07 September 2022. Payment date: 15 October 2022. Payout ratio is a comfortable 3.8% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.7%). Anuncio • Aug 24
Chemfab Alkalis Limited to Report Q4, 2023 Results on May 30, 2023 Chemfab Alkalis Limited announced that they will report Q4, 2023 results on May 30, 2023 Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 17% share price gain to ₹283, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 78% over the past three years. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 28% share price gain to ₹225, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 40% over the past three years. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Non Executive Director Nitin Cowlagi was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 28
First quarter 2023 earnings released: EPS: ₹15.10 (vs ₹2.18 in 1Q 2022) First quarter 2023 results: EPS: ₹15.10 (up from ₹2.18 in 1Q 2022). Revenue: ₹987.7m (up 110% from 1Q 2022). Net income: ₹213.5m (up ₹182.8m from 1Q 2022). Profit margin: 22% (up from 6.5% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Board Change • Jul 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Non Executive Director Nitin Cowlagi was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 27
Full year 2022 earnings released: EPS: ₹2.53 (vs ₹5.81 loss in FY 2021) Full year 2022 results: EPS: ₹2.53 (up from ₹5.81 loss in FY 2021). Revenue: ₹2.77b (up 53% from FY 2021). Net income: ₹287.5m (up ₹368.8m from FY 2021). Profit margin: 10% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • May 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹194, the stock trades at a trailing P/E ratio of 67.5x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improved over the past week After last week's 17% share price gain to ₹243, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 61% over the past three years. Reported Earnings • Feb 02
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹8.56 (up from ₹0.88 in 3Q 2021). Revenue: ₹777.4m (up 68% from 3Q 2021). Net income: ₹120.4m (up ₹108.1m from 3Q 2021). Profit margin: 16% (up from 2.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 06
Full year 2021 earnings released: ₹5.81 loss per share (vs ₹18.27 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: ₹1.81b (down 12% from FY 2020). Net loss: ₹81.3m (down 132% from profit in FY 2020). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • May 24
Full year 2021 earnings released: ₹5.81 loss per share (vs ₹18.27 profit in FY 2020) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: ₹1.82b (down 11% from FY 2020). Net loss: ₹81.3m (down 132% from profit in FY 2020). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improved over the past week After last week's 25% share price gain to ₹167, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 22% over the past three years. Reported Earnings • Feb 01
Third quarter 2021 earnings released: EPS ₹0.88 (vs ₹3.98 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹462.7m (down 9.9% from 3Q 2020). Net income: ₹12.3m (down 78% from 3Q 2020). Profit margin: 2.7% (down from 11% in 3Q 2020). 
